Azeddine Atfi

Closest collaborators

The 25 strongest of 31 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Mohammed Shawkat Razzaque · 7 shared papers, 2019–2026 · strength 1.35
   • Paper NF1 loss of function as an alternative initiating event in pancreatic ductal adenocarcinoma. DOI 10.1016/j.celrep.2026.117066↗
   • Paper Deciphering epithelial-to-mesenchymal transition in pancreatic cancer. DOI 10.1016/bs.acr.2023.02.008↗
   • Paper TGIF1-Twist1 axis in pancreatic ductal adenocarcinoma. DOI 10.1016/j.csbj.2020.09.023↗
2. Keli Xu · 6 shared papers, 2019–2026 · strength 1.21
   • Paper Lfng-expressing centroacinar cell is a unique cell-of-origin for p53 deficient pancreatic cancer. DOI 10.1038/s41388-024-03226-7↗
   • Paper NF1 loss of function as an alternative initiating event in pancreatic ductal adenocarcinoma. DOI 10.1016/j.celrep.2026.117066↗
   • Paper Antagonism between Prdm16 and Smad4 specifies the trajectory and progression of pancreatic cancer. DOI 10.1083/jcb.202203036↗
3. Parash Parajuli · 6 shared papers, 2019–2026 · strength 1.11
   • Paper NF1 loss of function as an alternative initiating event in pancreatic ductal adenocarcinoma. DOI 10.1016/j.celrep.2026.117066↗
   • Paper Deciphering epithelial-to-mesenchymal transition in pancreatic cancer. DOI 10.1016/bs.acr.2023.02.008↗
   • Paper Antagonism between Prdm16 and Smad4 specifies the trajectory and progression of pancreatic cancer. DOI 10.1083/jcb.202203036↗
4. Creighton Friend · 4 shared papers, 2022–2026 · strength 0.88
   • Paper NF1 loss of function as an alternative initiating event in pancreatic ductal adenocarcinoma. DOI 10.1016/j.celrep.2026.117066↗
   • Paper Deciphering epithelial-to-mesenchymal transition in pancreatic cancer. DOI 10.1016/bs.acr.2023.02.008↗
   • Paper Antagonism between Prdm16 and Smad4 specifies the trajectory and progression of pancreatic cancer. DOI 10.1083/jcb.202203036↗
5. Eric G. Hurwitz · 3 shared papers, 2022–2026 · strength 0.62
   • Paper NF1 loss of function as an alternative initiating event in pancreatic ductal adenocarcinoma. DOI 10.1016/j.celrep.2026.117066↗
   • Paper Antagonism between Prdm16 and Smad4 specifies the trajectory and progression of pancreatic cancer. DOI 10.1083/jcb.202203036↗
   • Paper NF1 loss of function as an alternative initiating event in pancreatic ductal adenocarcinoma. DOI 10.1016/j.celrep.2022.111623↗
6. Gopalakrishnan Ramakrishnan · 2 shared papers, 2022–2026 · strength 0.46
   • Paper NF1 loss of function as an alternative initiating event in pancreatic ductal adenocarcinoma. DOI 10.1016/j.celrep.2026.117066↗
   • Paper NF1 loss of function as an alternative initiating event in pancreatic ductal adenocarcinoma. DOI 10.1016/j.celrep.2022.111623↗
7. Sahar F. Bannoura · 2 shared papers, 2025–2026 · strength 0.37
   • Paper XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant p… DOI 10.1016/j.canlet.2026.218804↗
   • Paper Co-targeting KRAS and Exportin1 as an effective therapeutic strategy for KRASG12D mutant pancreatic ductal adenocarcino… DOI 10.1101/2025.11.21.689857↗
8. P. A. Philip · 2 shared papers, 2025–2026 · strength 0.37
   • Paper XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant p… DOI 10.1016/j.canlet.2026.218804↗
   • Paper Co-targeting KRAS and Exportin1 as an effective therapeutic strategy for KRASG12D mutant pancreatic ductal adenocarcino… DOI 10.1101/2025.11.21.689857↗
9. Bin Bao · 2 shared papers, 2025–2026 · strength 0.37
   • Paper XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant p… DOI 10.1016/j.canlet.2026.218804↗
   • Paper Co-targeting KRAS and Exportin1 as an effective therapeutic strategy for KRASG12D mutant pancreatic ductal adenocarcino… DOI 10.1101/2025.11.21.689857↗
10. Md. Hafiz Uddin · 2 shared papers, 2025–2026 · strength 0.37
    • Paper XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant p… DOI 10.1016/j.canlet.2026.218804↗
    • Paper Co-targeting KRAS and Exportin1 as an effective therapeutic strategy for KRASG12D mutant pancreatic ductal adenocarcino… DOI 10.1101/2025.11.21.689857↗
11. Boris Pasche · 2 shared papers, 2025–2026 · strength 0.37
    • Paper XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant p… DOI 10.1016/j.canlet.2026.218804↗
    • Paper Co-targeting KRAS and Exportin1 as an effective therapeutic strategy for KRASG12D mutant pancreatic ductal adenocarcino… DOI 10.1101/2025.11.21.689857↗
12. Husain Yar Khan · 2 shared papers, 2025–2026 · strength 0.37
    • Paper XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant p… DOI 10.1016/j.canlet.2026.218804↗
    • Paper Co-targeting KRAS and Exportin1 as an effective therapeutic strategy for KRASG12D mutant pancreatic ductal adenocarcino… DOI 10.1101/2025.11.21.689857↗
13. Eliza Wright Beal · 2 shared papers, 2025–2026 · strength 0.37
    • Paper XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant p… DOI 10.1016/j.canlet.2026.218804↗
    • Paper Co-targeting KRAS and Exportin1 as an effective therapeutic strategy for KRASG12D mutant pancreatic ductal adenocarcino… DOI 10.1101/2025.11.21.689857↗
14. Amro Aboukameel · 2 shared papers, 2025–2026 · strength 0.37
    • Paper XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant p… DOI 10.1016/j.canlet.2026.218804↗
    • Paper Co-targeting KRAS and Exportin1 as an effective therapeutic strategy for KRASG12D mutant pancreatic ductal adenocarcino… DOI 10.1101/2025.11.21.689857↗
15. Muhammad Wasif Saif · 2 shared papers, 2025–2026 · strength 0.37
    • Paper XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant p… DOI 10.1016/j.canlet.2026.218804↗
    • Paper Co-targeting KRAS and Exportin1 as an effective therapeutic strategy for KRASG12D mutant pancreatic ductal adenocarcino… DOI 10.1101/2025.11.21.689857↗
16. Ramzi M. Mohammad · 2 shared papers, 2025–2026 · strength 0.37
    • Paper XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant p… DOI 10.1016/j.canlet.2026.218804↗
    • Paper Co-targeting KRAS and Exportin1 as an effective therapeutic strategy for KRASG12D mutant pancreatic ductal adenocarcino… DOI 10.1101/2025.11.21.689857↗
17. Anthony Frank Shields · 2 shared papers, 2025–2026 · strength 0.37
    • Paper XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant p… DOI 10.1016/j.canlet.2026.218804↗
    • Paper Co-targeting KRAS and Exportin1 as an effective therapeutic strategy for KRASG12D mutant pancreatic ductal adenocarcino… DOI 10.1101/2025.11.21.689857↗
18. Asfar Sohail Azmi · 2 shared papers, 2025–2026 · strength 0.37
    • Paper XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant p… DOI 10.1016/j.canlet.2026.218804↗
    • Paper Co-targeting KRAS and Exportin1 as an effective therapeutic strategy for KRASG12D mutant pancreatic ductal adenocarcino… DOI 10.1101/2025.11.21.689857↗
19. Bassel F. El‐Rayes · 2 shared papers, 2025–2026 · strength 0.37
    • Paper XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant p… DOI 10.1016/j.canlet.2026.218804↗
    • Paper Co-targeting KRAS and Exportin1 as an effective therapeutic strategy for KRASG12D mutant pancreatic ductal adenocarcino… DOI 10.1101/2025.11.21.689857↗
20. Wen-Cheng Chung · 1 shared paper, 2025 · strength 0.37
    • Paper Lfng-expressing centroacinar cell is a unique cell-of-origin for p53 deficient pancreatic cancer. DOI 10.1038/s41388-024-03226-7↗
21. Shubing Zhang · 1 shared paper, 2025 · strength 0.37
    • Paper Lfng-expressing centroacinar cell is a unique cell-of-origin for p53 deficient pancreatic cancer. DOI 10.1038/s41388-024-03226-7↗
22. Steve H. Kim · 1 shared paper, 2025 · strength 0.17
    • Paper Co-targeting KRAS and Exportin1 as an effective therapeutic strategy for KRASG12D mutant pancreatic ductal adenocarcino… DOI 10.1101/2025.11.21.689857↗
23. Allyn Bryan · 1 shared paper, 2023 · strength 0.16
    • Paper Antagonism between Prdm16 and Smad4 specifies the trajectory and progression of pancreatic cancer. DOI 10.1083/jcb.202203036↗
24. Paul B. Fisher · 1 shared paper, 2023 · strength 0.15
    • Paper Cytoplasmic-delivery of polyinosine-polycytidylic acid inhibits pancreatic cancer progression increasing survival by ac… DOI 10.1136/jitc-2023-007624↗
25. Rajan Gogna · 1 shared paper, 2023 · strength 0.15
    • Paper Cytoplasmic-delivery of polyinosine-polycytidylic acid inhibits pancreatic cancer progression increasing survival by ac… DOI 10.1136/jitc-2023-007624↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.